Literature DB >> 11306984

Invited lecture: activation of the epithelial mesenchymal trophic unit in the pathogenesis of asthma.

S T Holgate1, P M Lackie, P H Howarth, W R Roche, S M Puddicombe, A Richter, S J Wilson, J W Holloway, D E Davies.   

Abstract

BACKGROUND: A recent NIH Workshop and an ERS Task Force concluded that more work was needed to understand mechanisms of severe and chronic asthma. This report describes a series of studies that identify aberrant epithelial mesenchymal signalling in the airways as an important event in maintaining inflammation and driving remodelling in response to environmental injury.
METHODS: Immunohistochemistry, genotyping and functional studies conducted on cultured asthmatic cells and mucosal biopsies were used to identify biochemical pathways involved in epithelial injury and repair in asthma and their relationship to disease severity.
RESULTS: Our findings suggest that the asthmatic state results from an interaction between a susceptible epithelium and Th-2-mediated inflammation to alter the communication between the epithelium and the underlying mesenchyme - the epithelial mesenchymal trophic unit - leading to disease persistence, airway remodelling and refractoriness to corticosteroid treatment.
CONCLUSIONS: Asthma is more than an inflammatory disorder, but requires engagement of important signalling pathways involved in epithelial repair and tissue remodelling. These pathways involving EGFRs and TGF-betaRs provide targets against which to develop novel therapies for chronic asthma. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11306984     DOI: 10.1159/000053726

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  15 in total

Review 1.  Airway remodeling: a potential therapeutic target in asthma.

Authors:  Wei-Xi Zhang; Chang-Chong Li
Journal:  World J Pediatr       Date:  2011-05-15       Impact factor: 2.764

Review 2.  Targeting insulin-like growth factor-I and insulin-like growth factor-binding protein-3 signaling pathways. A novel therapeutic approach for asthma.

Authors:  Hyun Lee; So Ri Kim; Youngman Oh; Seong Ho Cho; Robert P Schleimer; Yong Chul Lee
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

Review 3.  Allergen-induced airway remodelling.

Authors:  C M Lloyd; D S Robinson
Journal:  Eur Respir J       Date:  2007-05       Impact factor: 16.671

Review 4.  Antenatal endogenous and exogenous glucocorticoids and their impact on immune ontogeny and long-term immunity.

Authors:  María Emilia Solano; Megan C Holmes; Paul R Mittelstadt; Karen E Chapman; Eva Tolosa
Journal:  Semin Immunopathol       Date:  2016-07-28       Impact factor: 9.623

Review 5.  ADAM 33 and its association with airway remodeling and hyperresponsiveness in asthma.

Authors:  Stephen T Holgate; Donna E Davies; Steuart Rorke; Julie Cakebread; Gillian Murphy; Robert M Powell; John W Holloway
Journal:  Clin Rev Allergy Immunol       Date:  2004-08       Impact factor: 8.667

Review 6.  Is there a role for treatment of asthma with omalizumab?

Authors:  H Milgrom
Journal:  Arch Dis Child       Date:  2003-01       Impact factor: 3.791

7.  Escape from the matrix: multiple mechanisms for fibroblast activation in pulmonary fibrosis.

Authors:  Geoffrey J Laurent; Robin J McAnulty; Michael Hill; Rachel Chambers
Journal:  Proc Am Thorac Soc       Date:  2008-04-15

Review 8.  The role of ADAM33 in the pathogenesis of asthma.

Authors:  Julie A Cakebread; H-M Haitchi; John W Holloway; Robert M Powell; Tim Keith; Donna E Davies; Stephen T Holgate
Journal:  Springer Semin Immunopathol       Date:  2003-11-15

Review 9.  Association of CFTR gene mutation with bronchial asthma.

Authors:  Nutan Maurya; Shally Awasthi; Pratibha Dixit
Journal:  Indian J Med Res       Date:  2012-04       Impact factor: 2.375

Review 10.  Chronic inflammation and asthma.

Authors:  Jenna R Murdoch; Clare M Lloyd
Journal:  Mutat Res       Date:  2009-09-19       Impact factor: 2.433

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.